 Biocept Inc NASDAQ:BIOC announced plans Tuesday to collaborate with Protean BioDiagnostics Inc to research the ability of its own Target Selector molecular assays to determine the status of EGFR mutations in non-small cell lung cancer NSCLC patients. Protean also expects to validate the analytical performance of a laboratory developed test LDT based on Biocepts EGFR assay test kit in accordance with the requirements of the College of American Pathologists CAP validation process, the company said. 